Targeting the A
A3
adenosine receptor
cytokine release syndrome
immunotherapy
treatment
Journal
Drug design, development and therapy
ISSN: 1177-8881
Titre abrégé: Drug Des Devel Ther
Pays: New Zealand
ID NLM: 101475745
Informations de publication
Date de publication:
2019
2019
Historique:
entrez:
22
2
2019
pubmed:
23
2
2019
medline:
10
8
2019
Statut:
epublish
Résumé
Cancer patients undergoing immunotherapy may develop cytokine release syndrome (CRS), an inflammatory cytokine storm condition, followed by neurotoxic manifestations and may be life-threatening. The current treatments for CRS successfully reduce the inflammatory response but may limit the anticancer effect of the given immunotherapy and fail to overcome the neurotoxic adverse events. Adenosine, a ubiquitous purine nucleoside, induces a plethora of effects in the body via its binding to four adenosine receptors A
Identifiants
pubmed: 30787591
doi: 10.2147/DDDT.S195294
pii: dddt-13-491
pmc: PMC6363488
doi:
Substances chimiques
Adenosine A3 Receptor Agonists
0
Anti-Inflammatory Agents, Non-Steroidal
0
Receptor, Adenosine A3
0
Types de publication
Journal Article
Review
Langues
eng
Pagination
491-497Déclaration de conflit d'intérêts
Disclosure Shira Cohen is a consultant at Can-Fite BioPharma Ltd. Pnina Fishman is an executive at Can-Fite BioPharma Ltd. and has shares and stock options. The authors report no other conflicts of interest in this work.
Références
J Cell Physiol. 2000 Jun;183(3):393-8
pubmed: 10797314
J Cell Physiol. 2001 Jan;186(1):19-23
pubmed: 11147810
Annu Rev Neurosci. 2001;24:31-55
pubmed: 11283304
Ann Rheum Dis. 2001 Aug;60(8):729-35
pubmed: 11454634
J Biol Regul Homeost Agents. 2002 Apr-Jun;16(2):105-9
pubmed: 12144121
Eur J Pharmacol. 2003 Apr 18;466(3):323-9
pubmed: 12694816
Mol Cell Biochem. 2003 Sep;251(1-2):153-9
pubmed: 14575317
Mol Pharmacol. 2004 Mar;65(3):711-9
pubmed: 14978250
Clin Cancer Res. 2004 Jul 1;10(13):4472-9
pubmed: 15240539
Clin Cancer Res. 2004 Sep 1;10(17):5895-901
pubmed: 15355922
Int J Clin Pharmacol Ther. 2004 Oct;42(10):534-42
pubmed: 15516022
Arthritis Rheum. 2005 Mar;52(3):818-25
pubmed: 15751095
Pharmacol Rev. 2005 Jun;57(2):163-72
pubmed: 15914465
Crit Care Med. 2005 Nov;33(11):2457-64
pubmed: 16276166
Neurosci Lett. 2006 Mar 20;396(1):1-6
pubmed: 16324785
Arthritis Res Ther. 2006;8(1):R33
pubmed: 16507132
J Rheumatol. 2007 Jan;34(1):20-6
pubmed: 17216675
J Rheumatol. 2008 Jan;35(1):41-8
pubmed: 18050382
J Pathol. 2008 Jan;214(2):149-60
pubmed: 18161752
Biochem Pharmacol. 2008 Aug 15;76(4):482-94
pubmed: 18602896
Int J Oncol. 2008 Aug;33(2):287-95
pubmed: 18636149
Biol Blood Marrow Transplant. 2009 Apr;15(4):421-31
pubmed: 19285629
Cell Immunol. 2009;258(2):115-22
pubmed: 19426966
Arthritis Rheum. 2009 Oct;60(10):3061-71
pubmed: 19790055
Cold Spring Harb Perspect Biol. 2009 Dec;1(6):a001651
pubmed: 20457564
Expert Rev Clin Immunol. 2009 Sep;5(5):499-521
pubmed: 20477639
Am J Physiol Lung Cell Mol Physiol. 2010 Oct;299(4):L502-12
pubmed: 20639349
J Pharmacol Exp Ther. 2010 Nov;335(2):434-42
pubmed: 20668053
Br J Dermatol. 2010 Nov;163(5):977-85
pubmed: 20716228
Immunobiology. 2011 Sep;216(9):997-1003
pubmed: 21514967
J Cell Physiol. 2011 Sep;226(9):2438-47
pubmed: 21660967
Mod Rheumatol. 2012 Feb;22(1):109-15
pubmed: 21667343
Mol Cell Biol. 1990 May;10(5):2327-34
pubmed: 2183031
Int J Mol Med. 2011 Nov;28(5):727-31
pubmed: 21887476
Nat Rev Cancer. 2011 Oct 24;11(11):805-12
pubmed: 22020206
Clin Sci (Lond). 2012 Feb;122(4):143-59
pubmed: 22029668
Drug Discov Today. 2012 Apr;17(7-8):359-66
pubmed: 22033198
Arthritis Res Ther. 2011;13(6):R197
pubmed: 22146575
Nature. 2011 Dec 21;480(7378):480-9
pubmed: 22193102
Nat Rev Immunol. 2012 Mar 22;12(4):269-81
pubmed: 22437939
Oncologist. 2013;18(1):25-6
pubmed: 23299770
Nat Rev Clin Oncol. 2013 May;10(5):267-76
pubmed: 23546520
PLoS One. 2013 May 31;8(5):e65561
pubmed: 23741498
Cancer Lett. 2014 Feb 28;343(2):172-8
pubmed: 24141191
Semin Arthritis Rheum. 2014 Feb;43(4):458-69
pubmed: 24262929
Sci Transl Med. 2014 Feb 19;6(224):224ra25
pubmed: 24553386
Cancer J. 2014 Mar-Apr;20(2):119-22
pubmed: 24667956
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
N Engl J Med. 2014 Oct 16;371(16):1507-17
pubmed: 25317870
Immunotherapy. 2014;6(12):1265-78
pubmed: 25524383
Trends Pharmacol Sci. 2016 Jun;37(6):419-434
pubmed: 26944097
J Clin Invest. 2016 Jun 1;126(6):2123-38
pubmed: 27111235
Crit Care. 2017 Apr 14;21(1):89
pubmed: 28407743
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
N Engl J Med. 2018 Feb 1;378(5):449-459
pubmed: 29385376
Biomark Res. 2018 Jan 22;6:4
pubmed: 29387417
Ann Hematol. 2018 May;97(5):781-789
pubmed: 29417201
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Immunol Lett. 2018 Apr 24;:null
pubmed: 29702147
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
Physiol Rev. 2018 Jul 1;98(3):1591-1625
pubmed: 29848236
J Immunol Res. 2018 May 15;2018:2310970
pubmed: 29862305
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Exp Brain Res. 2018 Sep 11;:null
pubmed: 30206669
Hematology. 2019 Dec;24(1):199-207
pubmed: 30479190
Eur J Pharmacol. 1998 Oct 9;358(3):261-8
pubmed: 9822893